Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of giredestrant compared with fulvestrant (plus a CDK4/6 inhibitor) in ER-positive, HER2-negative advanced br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Estrogen Receptor-positive Advanced Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor
• Fulvestrant (fulvestrant)
• Giredestrant (giredestrant)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Status: RECRUITING